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Local recurrence is the most common cause of failure after head
and neck cancer surgery and the most important factor which
predisposes to recurrence is incomplete surgical resection margins
(Snow et al, 1989; Jones et al, 1992). Recurrent squamous cell
cancer of the head and neck (SCCHN) causes significant
morbidity including effects on speech and swallowing. It is a
disease with a very poor prognosis as currently available therapies
including re-irradiation (Nickers, 1997) and chemotherapy
(Clavel, 1994) all have poor response rates which are short lasting
(Forestiere, 1994). The reason for this is unclear but is likely to be
multifactorial in nature. One factor which may be important in
resistance to therapy is loss of function of the tumour suppressor
gene p53. It has been shown that inactivation of the p53 tumour
suppressor gene is one of the major predictors of failure to respond
to radiotherapy and chemotherapy in many tumour types
(McIlwrath et al, 1994; Buttitta et al, 1997; Cutilli et al, 1998).
This is because p53 plays a major role in the induction of apoptosis
in response to genotoxic agents such as radiotherapy and
chemotherapy (Lowe et al, 1993; Huang et al, 1996). Therefore
one possible explanation for the poor response rates in recurrent
SCCHN to radiotherapy and chemotherapy could be due to a high
incidence of p53 inactivation in this disease. No previous studies
have been reported on the incidence or mechanism of p53
inactivation in recurrent head and neck cancer. The objectives of
this study were therefore to determine the incidence of p53
mutations in this disease and also gain insight into other mech-
anisms of p53 inactivation such as binding by the cellular protein
mdm2 (Oliner et al, 1992; Haupt et al, 1997) and viral protein
HPV E6 (Scheffner et al, 1990; Lechner et al, 1992). To determine
the incidence of p53 inactivation in recurrent HNSCC, 22 recur-
rent tumours from patients previously treated with radiotherapy ±
surgery were analysed. The p53 status of each tumour was
analysed by sequencing and by immunohistochemistry. Tumours
were further analysed for mdm2 overexpression by immunohisto-
chemistry and for human papillomavirus (HPV) infection by poly-
merase chain reaction (PCR) of tumour DNA. Overall we have
shown that there is a greater incidence of p53 mutations in re-
current disease compared to primary disease. However, the in-
cidence of HPV infection and mdm2 overexpression was similar
to reported studies in primary disease. Nevertheless, we show that
the overall incidence of p53 alterations is very high at 95%. This
may be one factor which accounts for the poor response of this
disease to radiotherapy and chemotherapy and implies new
therapies which either restore p53 function or which act in a p53
indpendent manner may prove to be beneficial in this disease.
METHODS
Tumour collection
Patients with recurrent SCCHN gave consent for biopsies to be
taken from the recurrent tumours. Core biopsies were taken using
a 14 gauge tru-cut needle under local anaesthetic. One sample was
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was fixed in phosphate-buffered formalin, embedded in paraffin
from which 5-mm sections were cut for immunohistochemical
analysis.
Immunohistochemistry
Immunohistochemistry for p53
Immunohistochemistry was carried out on formalin-fixed
paraffin-embedded tumours cut into 5-mm sections. Slides were
deparaffinized in xylene, hydrated through ethanols 100%, 90%,
70% and then water, then washed in PBS (phosphate-buffered
saline). Antigen retrieval was carried out by microwaving in
citrate buffer pH 6.0 at 500 W for 25 min and then allowed to cool
over 20 min. The slides were washed in PBS for 5 min and then
endogenous peroxide activity blocked with 3% v/v hydrogen
peroxide in methanol for 10 min. After washing in PBS for 5 min,
the slides were blocked with Universal blocking solution
(Biogenex) for 10 min, and then primary antibody (DO-1
Oncogene Science) at a dilution of 1/1000 in Dako antibody
diluent solution, added for 1 h at room temperature. Antigen
detection was done using a biotinylated second antibody followed
by streptavidin as supplied in the Biogenex link/label kit. The
chromogen used for detection was diaminobenzidine (Vector) for
3–10 min. The sections were counterstained with haematoxylin,
dehydrated in graded alcohols followed by xylene, and then
mounted in DPX mounting medium (BDH Chemicals). The
immunohistochemistry pattern was scored using a histoscore
based on intensity of staining and percentage of positive cells
staining and given a score out of a maximum of 6 (Table 1).
Immunohistochemistry for mdm2
The protocol used was as described for p53 immunohistochem-
istry. The primary antibody used was a mouse monoclonal anti-
body SMP14 (Dako) at a dilution of 1/50 in PBS. Mdm2 staining
was then scored by the % of cells staining positive and by the
intensity of staining as described above.
DNA extraction
Genomic DNA was isolated directly from frozen tumours by lysis
buffer containing 10 mM Tris–HCl, 10 mM EDTA, 10 mM sodium
chloride, 4% N-lauryl sarcosine and 2.75 mg ml–1 proteinase K,
followed by overnight digestion at 55°C and EtOH precipitation.
The resulting pellet was washed with 70% EtOH, dried, and resus-
pended in 100 ml TE and stored at 4°C.
p53 sequencing
Exons 4 to 9 were sequenced using DNA extracted from pre-treat-
ment tumour biopsies. This was done by Oncormed Corporation,
Gaithersburg, Maryland.
HPV analysis
The presence of HPV in tumour DNA was assessed by PCR. The
primers for the amplification of HPV 16 and HPV 18 have been
described previously (Yeudall et al, 1991) and amplify fragments
of the E6/E7 (HPV 16) or E6 regions (HPV 18), which are 165 and
99 bp respectively. HPV 33 primers were those as described by
Haraf et al (1996).
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Table 1
Intensity of staining Score Cells staining positive (%) Score
None 0 0 0
Mild 1 5–20 1
Moderate 2 20–80 2
Severe 3 > 80 3
Table 2 Primary tumour, site of recurrence and previous treatment
Pt no. Sex Age Primary Site of recurrence Prior therapy
Chemotherapy Radiotherapy Surgery
1 M 61 Piriform fossa Left cervical Yes Yes No
2 M 74 Hypopharynx Bilateral cervical Yes Yes No
3 M 32 Tongue Right submandibular No Yes Yes
4 F 80 Palate Right clavicular area No Yes Yes
5 F 68 Floor of mouth Right neck-post triangle No Yes Yes
6 F 38 Left auditory canal Left cervical Yes Yes No
7 M 53 Left temple Left preauricular area No Yes Yes
8 F 72 Right retromolar trigone Right cervical No Yes No
9 M 56 Floor of mouth Left submandibular No Yes Yes
10 M 88 Left palatoglossal fold Bilateral cervical No Yes Yes
11 M 76 Supraglottic larynx Left cervical No Yes No
12 M 82 Retromolar trigone Left cervical No Yes No
13 M 62 Tongue Left cervical No Yes Yes
14 M 75 Supraglottic larynx Left submandibular No Yes Yes
15 M 60 Larynx Right cervical No Yes Yes
16 F 64 Piriform fossa Right cervical Yes Yes No
17 M 59 Oropharynx Left clavicular No Yes Yes
18 F 58 Supraglottic larynx Left cervical No Yes Yes
19 F 59 Oropharynx Left cervical No Yes Yes
20 M 51 Tongue Right cervical No Yes Yes
21 F 75 Post cricoid Left cervical No Yes No
22 M 65 Supraglottic larynx Left supraclavicular No Yes YesThe HPV16 primers were: 5¢-TTAATTAGGTGTATTAACTG-
3¢ and 5¢-TGCATGATTACAGCRGGGTT-3¢. The HPV18 primers
were: 5¢-ATCTGTGTGCACGGAACTAAC-3¢ and 5¢-AATGCA-
AATTCAAATACCTC-3¢. The HPV33 primers were: 5¢-GTGC-
CAAGCATTGGAGACAA-3¢ and 5¢-GATAAGAACCGCAAAC
-ACAG-3¢.
SiHa DNA (single copy HPV 16) and HeLa DNA (HPV 18)
were used as positive controls. HPV amplification was carried
out at 95°C for 3 min, then 30 cycles of 95°C for 30 s, 55°C for
30 s, 72°C for 30 s, followed by a final extension time of 
10 min at 72°C. An aliquot was run on a 1% agarose gel (Nu-
Sieve) containing 0.5 mg ml–1 ethidium bromide in TBE buffer
and then photographed under UV light to check for correct
amplification.
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Table 3 p53 sequence of recurrent squamous cell cancers studied
Pt no. Exon Codon Base-pair change Amino acid change p53 Gene sequencing
(Exons 4–9)
1 5 376 Splice site mutation Truncated protein Mutant-non-sense
2 8 273 CGT to TGT Arginine to cysteine Mutant-mis-sense
3 8 307 Deletion G Stop signal Mutant-non-sense
4 6 51 splice site mutn AG to AA Truncated protein Mutant-non-sense
5 5 141 TGC to TAC Cysteine to tyrosine Mutant-mis-sense
6 9 336 Frameshift mutation Stop signal Mutant-non-sense
7 8 280 AGA to ATA Arginine to isoleucine Mutant-mis-sense
8 8 282 CGG to TGG Arginine to tryptophan Mutant-mis-sense
9w t Wild type
10 wt Wild type
11 wt Wild type
12 8 266 GGA to TGA Glycine to stop signal-truncated protein Mutant-non-sense
13 6 205 TAT to TGT Tyrosine to cysteine Mutant-mis-sense
14 wt Wild type
15 7 233 11 bp insertion Stop signal at codon 250 Mutant-non-sense
16 9 317 CAG to TAG Glutamine to stop signal-truncated protein Mutant-non-sense
17 wt Wild type
18 6 222 Deletion G Stop signal Mutant-non-sense
19 wt Wild type
20 5 163 TAC to TGC Tyrosine to cysteine Mutant-mis-sense
21 wt Wild type
22 5 167 10 bp deletion Stop signal Mutant-non-sense
Of 22 tumours studied, 15 had mutant p53 and 7 had wild type p53. Of the mutant p53 sequences, 6 were missense mutations and 9 were nonsense mutations.
Table 4 p53 and mdm2 immunohistochemistry histoscores and HPV PCR analysis in squamous cell cancers studied
Patient no. p53 gene seq. p53 IHC p53 histoscore mdm2 IHC mdm2 histoscore HPV16 HPV18/33
1 Mutant-mis-sense – 0 + 2 – –
2 Mutant-non-sense + 4 – 0 – –
3 Mutant-non-sense – 0 – 0 + –
4 Mutant-mis-sense – 0 + 2 – –
5 Mutant-non-sense + 6 – 0 – –
6 Mutant-mis-sense + 6 + 4 – –
7 Mutant-mis-sense + 6 – 0 – –
8 Mutant-mis-sense + 5 + 2 – –
9 Wild type + 5 + 3 – –
10 Wild type – 0 – 0 + –
11 Wild type – 0 + 5 – –
12 Mutant-non-sense – 0 + 3 + –
13 Mutant-mis-sense + 4 – 0 + –
14 Wild type + 2 – 0 – –
15 Mutant-non-sense – 0 – 0 + –
16 Mutant-non-sense – 0 – 0 + –
17 Wild type + 2 + 5 + –
18 Mutant-non-sense – 0 + 4 – –
19 Wild type – 0 – 0 + –
20 Mutant-mis-sense + 4 – 0 – –
21 Wild type + 6 + 5 – –
22 Mutant-non-sense – 0 + 4 – –
p53 immunohistochemistry histoscore correlated with the type of gene sequence; non-sense mutations had low histoscores and mis-sense mutations had high
histoscores. Mdm2 protein expression was detected in 11 tumours and HPV16 detected in eight tumours. HPV18 and 33 DNA were not detected in any tumour.p53 alterations in recurrent SCC 395
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RESULTS
Primary tumour, site of recurrence and previous
treatment
The primary tumour, site of recurrence and previous therapy for
each patient studied are shown in Table 2. The mean age was 64
and the male to female ratio was 14:8. All patients had received
radiotherapy. In addition, four patients had received chemotherapy
and 14 patients had had surgery. The site of tumour recurrence was
most commonly regional in the site of draining lymph nodes.
Incidence of p53 mutation in recurrent SCCHN is high
and type of mutation correlates with
immunohistochemistry
The p53 sequence and immunohistochemistry for each tumour is
shown in Tables 3 and 4. Of the 22 tumours studied, 15 had muta-
tions in the p53 gene of which six were mis-sense mutations and
nine were non-sense mutations. Generally, the immunohistochem-
istry pattern correlated directly with the type of p53 mutation, i.e.
mis-sense mutations gave high scores and non-sense mutations
gave low scores. One patient (patient 6) had a non-sense mutation
yet stained positively by immunohistochemistry. The site of the
mutation in this patient’s p53 gene was in codon 9 and this would
account for its detection by immunohistochemistry using the DO-
1 antibody. Of the seven patients with wild-type p53 sequence,
five were negative on immunohistochemistry (tumours 10, 11, 14,
17, 19) and two were positive indicating overexpression of wild-
type p53 (tumours 9, 21). Examples of p53 immunohistochemistry
with the relevant histoscores is shown in Figure 1.
Incidence of HPV infection and mdm2 overexpression
Eight tumours were positive for HPV DNA, all of which were
serotype HPV 16. Of these, five were in tumours with mutant p53
and three were in tumours with wild-type p53. A typical positive
PCR reaction for HPV 16 is shown in Figure 2.
Mdm2 expression was detected in 11 of the 22 tumours (50%).
Of these, five were weakly positive (histoscore = 2, 3) and six
were strongly positive (histoscore = 4, 5, 6). Mdm2 expression
was present in seven tumours with mutant p53 and in four tumours
with wild-type p53.
A
Histoscore=3+3=6
B
Histoscore=3+2=5
C
Histoscore=2+2=4
D
Histoscore=1+1=2
Figure 1 Examples of p53 immunohistochemistry staining in SCCHN biopsies. Staining was graded using a histoscore grading system based on the intensity
of staining and the percentage of cells staining positively as described in Methods
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Figure 2 HPV 16 E6/7 analysis of tumour DNA by PCR. DNA from SiHa
cell line was used as a positive control for HPV16 E6/7. Tumour 17 is positive
for HPV 16 with the correct PCR product at 165 base pairsOf the five tumours with wild-type p53 sequence and negative
or weakly positive p53 immunohistochemistry, two had HPV 16
expression (tumours 10, 19), one had high expression of mdm2
(tumour 11), one tumour had both (tumour 17) and one had
neither. Of the two tumours with wild-type p53 and strongly posi-
tive p53 immunohistochemistry (tumours 9, 21), both had high
expression of mdm2 indicating inactivation by mdm2. Thus, six
of the seven tumours with wild-type p53 had inactivation of p53
either by HPV 16 infection or by overexpression of mdm2.
Examples of mdm2 immunohistochemistry in tumours 17 and 21
are shown in Figure 3.
DISCUSSION
In this paper we have shown that in recurrent SCCHN there is a
high incidence of p53 mutation. Fifteen of the 22 tumours (68%)
had either a p53 mutation or deletion. Of these, six were mis-sense
mutations, whereas nine had non-sense inactivation. The immuno-
histochemistry results correlated very well with the mutations
seen. Previous studies in primary head and neck cancer have
shown an incidence of p53 mutation of 38–53% (Brachmann et al,
1992; Boyle et al, 1993; Mao et al, 1996; Olshan et al, 1997; Koh
et al, 1998). It has been suggested that p53 mutation is an early
event in head and neck carcinogenesis. Boyle et al (1993) showed
an incidence of mutation of 19% in pre-invasive lesions increasing
to 43% in invasive lesions. However, Chung et al (1993) showed
that the frequency of p53 mutations did not increase with stage of
disease with a reported incidence of 47% in stage I/II disease and
37% in stage III/IV disease. In our study, we have reported an inci-
dence of p53 mutation in recurrent SCCHN of 68%, which is
higher than that reported for primary disease. We did not carry out
microdissection of tumour cells from surrounding normal cells in
the preparation of tumour DNA so it is possible that some tumours
with wild-type p53 gene sequence are in fact false-negatives and
therefore the incidence may be higher than 68%. Our figures (and
those reported for primary disease by other studies) are also based
upon sequencing exons 4–9 of the p53 gene. Although 95% of
mutations occur in these exons, some mutations occur in intron
regions and also other exons. Therefore the incidence of p53 muta-
tions in our study may be higher. Similarly, the incidence in previ-
ously published studies on primary head and neck cancer may also
be slightly higher than 38–53%. It is also possible that previous
studies in primary disease have underestimated the incidence of
p53 mutation due to the heterozygous nature of primary tumours
resulting in false-negative results on gene sequencing. In recurrent
tumours, clonal expansion of tumour cells refractory to radio-
therapy occurs and therefore the pickup rate for detecting p53
mutation may be more accurate. However, another possibility may
be the induction of p53 mutations by radiotherapy treatment itself
since radiation is a potent DNA damaging agent and induces
single and multiple base pair deletions in DNA. It is difficult to
distinguish between these two possibilities but one method could
be to prepare molecular probes to the p53 mutation in each recur-
rent tumour and then to use these probes to screen the primary
tumours to look for the mutation. This study is currently underway
and will be reported separately.
p53 can be inactivated by HPV due to the ability of HPV E6
protein to bind to and promote the degradation of the product of
the p53 gene (Levine, 1990; zur Hausen, 1994). Indeed, inactiva-
tion of p53 by HPV E6 is the major mechanism of p53 inactivation
in cervical carcinogenesis (zur Hausen, 1994) with approximately
80–90% of cervical cancers containing HPV DNA (Yoshikawa,
1991). Previous studies have shown HPV DNA in tumours of the
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p53
Tumour 17
Tumour 21
mdm2
Figure 3 Examples of p53 and mdm2 immunohistochemistry in tumours with wild-type p53 gene sequence. Tumour 17 has weak p53 staining but intense
mdm2 staining suggesting p53 inactivation by mdm2 overexpression. Tumour 21 has overexpression of wild type p53 and also intense mdm2 staining
suggesting p53 may be functional in this tumour but inactivated by high expression of mdm2p53 alterations in recurrent SCC 397
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head and neck but its prevalence varies from 10–58% (Haraf et al,
1996; Paz et al, 1997; Koh et al, 1998; Miguel et al, 1998). A
metanalysis by McKaig et al (1998) showed an overall incidence
of 34.5% with the predominant type being HPV 16. The incidence
also varies with tumour site with the highest prevalence being in
tonsillar carcinoma (Paz et al, 1997). In our study in recurrent
tumours of the head and neck, we found an overall incidence of
36% (8/22), all of which were HPV 16. These results were very
similar to the meta-analysis figures by McKaig for primary
tumours and this would suggest that HPV infection is not a major
aetiological factor in recurrent disease. One of the limitations of
our study, and of previously published studies, is that HPV detec-
tion is based upon PCR analysis of HPV DNA and not mRNA of
HPV E6–E7 regions. It is possible that PCR analysis of HPV DNA
can overestimate the presence of HPV due to cross-contamination
resulting in false-positives. Since RNA is readily degradable,
cross-contamination is less likely to result in false-positives.
Another advantage of using RNA is that it proves that any HPV
present in tumour cells is actually expressed at the mRNA level.
Some studies have reported HPV mRNA detection using in situ
hybridization of paraffin-embedded samples (Stoler et al, 1992). A
more accurate method, however, is to use reverse transcription
PCR (RT-PCR) as reported by Czegledy et al (1995). In our study,
DNA was used because the tumour samples were too small to
allow an adequate amount of RNA to be prepared. Of the eight
tumours which were positive for HPV, five were in tumours with
mutant p53 and three were in tumours with wild-type p53. These
figures are similar to those in primary tumours as reported by Koh
et al (1998) and suggests that p53 mutation and HPV positivity are
not mutually exclusive mechanisms of p53 inactivation. This is in
contrast to cervical carcinogenesis where p53 mutations are rare in
cases with HPV but common in malignancies devoid of HPV
infection (Park et al, 1990; Crook et al, 1991).
Another factor which can inactivate p53 is the cellular protein
mdm2. Mdm2 inhibits the transcriptional activity of p53 by
binding to the N terminus of p53 (Haupt et al, 1997) which in turn
leads to the degradation of p53 via the ubiquitin degradation
pathway. Thus amplification or overexpression of mdm2 can cause
p53 inactivation (Oliner et al, 1992). In primary SCCHN, mdm2
overexpression is reported to be 40% (Matsumura et al, 1996).
Girod et al (1995) showed an increase in mdm2 expression from
premalignant to malignant lesions indicating that this may be a
mechanism for inactivation of p53 early in head and neck carcino-
genesis. Further evidence to suggest this was reported by Pruneri
et al (1997), who showed that out of 17 laryngeal tumours over-
expressing mdm2, ten of these also overexpressed p53 and all ten
had wild-type p53 sequence. The importance of mdm2 over-
expression in recurrent SCCHN is unknown. In the small group of
tumours which we have studied, we have shown an incidence of
50% of which 5/11 were weakly positive and 6/11 were strongly
positive for mdm2. Mdm2 overexpression was present in seven
tumours with mutant p53 and in four tumours with wild-type p53,
and this also suggests that p53 mutation and mdm2 overexpression
are not mutually exclusive mechanisms of p53 inactivation. A
particularly intriguing observation is that of the seven tumours
which had wild-type p53 sequence, six were positive for either
HPV infection, mdm2 overexpression or both. Thus in wild-type
p53 tumours, the p53 gene is inactivated by other mechanisms
making the overall incidence of p53 inactivation in recurrent
SCCHN in this study to be 95% (21 out of 22 tumours). It is
unclear whether or not this overall incidence is greater than
primary SCCHN since no study has ever examined p53 mutation,
HPV infection and mdm2 overexpression in the same group of
tumours. The observation that the incidence of HPV infection and
mdm2 overexpression are similar to primary disease indicates that
these factors have a limited role in the aetiology of recurrent
SCCHN but may be more important in tumours in which the 
p53 gene is not inactivated by mutation. We have shown that the
incidence of p53 mutation in recurrent disease is higher than
primary disease and have suggested that one possible reason for
this could be due to DNA damage induced by radiation itself. We
are currently carrying out a study to determine the importance 
of this observation using molecular probes to each individual 
p53 mutation to screen the primary tumour for the mutation. 
The observation that recurrent disease has a very high incidence
of p53 inactivation is clearly important as p53 is central to apoptosis
induced by radiation and many chemotherapeutic agents. This may
account for the poor response of these tumours to both reirradiation
and chemotherapy. Therefore, new therapies which can restore p53
functionality, such as adenoviral mediated transfer of wild-type p53
(Roth et al, 1996), may be beneficial in this disease. Indeed, in vitro
and in vivo studies using such a technique have demonstrated
growth suppression in SCCHN cell lines (Liu et al, 1994, 1995;
Clayman et al, 1995). Results of a phase I study in patients with
recurrent SCCHN were also recently reported (Clayman et al, 1998)
and this showed evidence of tumour necrosis in some patients. Other
methods of restoring p53 function could be to use small molecules
to inactivate the mdm2 protein (Bottger et al, 1998), or drugs which
interfere with HPV E6 binding to wild-type p53 thus restoring func-
tion of p53. Recently, the selectively replicating adenovirus, Onyx-
015, which targets cells with mutant p53, was reported (Bischoff et
al, 1996; Heise et al, 1997). Results of a phase I study in patients
with recurrent head and neck cancer using this virus appear to be
promising (Ganly et al, 1997). Other approaches to the treatment of
this disease may be to use drugs which act in a p53-independent
manner. For example, Taxanes (Taxol) act by inducing p53-indepen-
dent apoptosis and have been successful in the treatment of refrac-
tory cisplatin-resistant ovarian cancer, a disease where there is also a
high incidence of p53 inactivation (Righetti et al, 1996; Buttitta et
al, 1997). Catimel et al (1994) has shown this agent to be effective in
recurrent SCCHN but there is no evidence yet that it has increased
benefit over cisplatin–5-fluorouracil chemotherapy. However,
newer agents which act in a p53-independent manner may prove to
be more beneficial.
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